Title: Evaluation of clinical efficacy, adverse reactions, and safety of PD-1 inhibitors combined
with chemotherapy when treating advanced gastric cancer
Version: 0 Date: 26 Aug 2023
Reviewer's report:
Dear Editor
This is a good manuscript reviewing “Synbiotic as an ameliorating factor in the health-related
quality of life in women with polycystic ovary syndrome. A randomized, triple-blind, placebo-
controlled trial”. The subject of the manuscript is fully consistent with the aims and scope of
the journal «BMC Women's Health».
The study was overall well-conducted and could be accepted after addressing the following
issues.
1- The study was overall well-conducted and could be accepted after addressing the following
issues.
2- Please write the full word when used for the first time in the text (line 7 &24).
3- How have completed the questioners by participant? What questions were asked and by whom
or face-to-face interview with trained researcher? Please explain in the method section.
4- Did dietary intake have evaluated such as a 24h food recall two times by research, in beginning
and end of the intervention.
5- The placebo and synbiotic sachets are described similar in packaging, texture and taste.
Perhaps a photo of the two forms of capsules could be added to the supplementary material so
readers can see how similar were. Please include packaging.
6- a photo of the two forms of capsules could be added to the supplementary material so readers
can see how similar were. Please include packaging.
7- How well does Synbiotic survive in the GI tract or is it absorbed quickly and acts systemically?
Perhaps more on ADME could be added to the introduction or discussion.
8- Is normal in a trial to get possible adverse effects such as headache or nausea that are reported
equally in both the placebo group and the test group. Were there really no possible adverse
effects or was it that there was no difference between the placebo group and the test group?
9- Do researcher see the Synbiotic really benefits the patients by limiting the symptoms.
10- This line implies no analysis using "intention to treat" statistics but this is mentioned
elsewhere so why not do ITT as well as the analysis reported?
11-  Please explain analyze the data both with and without these four patients. Did researcher
do no analysis using "intention to treat" statistics
12- The discussion section is too long to facilitate the understanding.
Title: Evaluation of clinical efficacy, adverse reactions, and safety of PD-1 inhibitors combined
with chemotherapy when treating advanced gastric cancer
Version: 0 Date: 26 Aug 2023
Reviewer's report:
Dear Editor
This is a good manuscript reviewing “Synbiotic as an ameliorating factor in the health-related
quality of life in women with polycystic ovary syndrome. A randomized, triple-blind, placebo-
controlled trial”. The subject of the manuscript is fully consistent with the aims and scope of
the journal «BMC Women's Health».
The study was overall well-conducted and could be accepted after addressing the following
issues.
1- The study was overall well-conducted and could be accepted after addressing the following
issues.
2- Please write the full word when used for the first time in the text (line 7 &24).
3- How have completed the questioners by participant? What questions were asked and by whom
or face-to-face interview with trained researcher? Please explain in the method section.
4- Did dietary intake have evaluated such as a 24h food recall two times by research, in beginning
and end of the intervention.
5- The placebo and synbiotic sachets are described similar in packaging, texture and taste.
Perhaps a photo of the two forms of capsules could be added to the supplementary material so
readers can see how similar were. Please include packaging.
6- a photo of the two forms of capsules could be added to the supplementary material so readers
can see how similar were. Please include packaging.
7- How well does Synbiotic survive in the GI tract or is it absorbed quickly and acts systemically?
Perhaps more on ADME could be added to the introduction or discussion.
8- Is normal in a trial to get possible adverse effects such as headache or nausea that are reported
equally in both the placebo group and the test group. Were there really no possible adverse
effects or was it that there was no difference between the placebo group and the test group?
9- Do researcher see the Synbiotic really benefits the patients by limiting the symptoms.
10- This line implies no analysis using "intention to treat" statistics but this is mentioned
elsewhere so why not do ITT as well as the analysis reported?
11-  Please explain analyze the data both with and without these four patients. Did researcher
do no analysis using "intention to treat" statistics
12- The discussion section is too long to facilitate the understanding.
Please review this paper.
user
Title: Evaluation of clinical efficacy, adverse reactions, and safety of PD-1 inhibitors combined
with chemotherapy when treating advanced gastric cancer
Version: 0 Date: 26 Aug 2023
Reviewer's report:
Dear Editor
This is a good manuscript reviewing “Synbiotic as an ameliorating factor in the health-related
quality of life in women with polycystic ovary syndrome. A randomized, triple-blind, placebo-
controlled trial”. The subject of the manuscript is fully consistent with the aims and scope of
the journal «BMC Women's Health».
The study was overall well-conducted and could be accepted after addressing the following
issues.
1- The study was overall well-conducted and could be accepted after addressing the following
issues.
2- Please write the full word when used for the first time in the text (line 7 &24).
3- How have completed the questioners by participant? What questions were asked and by whom
or face-to-face interview with trained researcher? Please explain in the method section.
4- Did dietary intake have evaluated such as a 24h food recall two times by research, in beginning
and end of the intervention.
5- The placebo and synbiotic sachets are described similar in packaging, texture and taste.
Perhaps a photo of the two forms of capsules could be added to the supplementary material so
readers can see how similar were. Please include packaging.
6- a photo of the two forms of capsules could be added to the supplementary material so readers
can see how similar were. Please include packaging.
7- How well does Synbiotic survive in the GI tract or is it absorbed quickly and acts systemically?
Perhaps more on ADME could be added to the introduction or discussion.
8- Is normal in a trial to get possible adverse effects such as headache or nausea that are reported
equally in both the placebo group and the test group. Were there really no possible adverse
effects or was it that there was no difference between the placebo group and the test group?
9- Do researcher see the Synbiotic really benefits the patients by limiting the symptoms.
10- This line implies no analysis using "intention to treat" statistics but this is mentioned
elsewhere so why not do ITT as well as the analysis reported?
11-  Please explain analyze the data both with and without these four patients. Did researcher
do no analysis using "intention to treat" statistics
12- The discussion section is too long to facilitate the understanding.
assistant